Baxter International (BAX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
23 Mar, 2026Voting matters and shareholder proposals
Election of nine directors is proposed, with all nominees recommended for approval by the board.
Advisory vote on executive compensation for 2025 is recommended for approval.
Ratification of the appointment of the independent registered public accounting firm for 2026 is recommended.
Approval of the Second Amended and Restated 2021 Incentive Plan is recommended.
Amendment to the Certificate of Incorporation to change board size is proposed.
Board of directors and corporate governance
Nine director nominees are listed for election at the annual meeting.
Board recommends all nominees for election.
Proposal to amend the Certificate of Incorporation to adjust board size is included.
Executive compensation and say-on-pay
Advisory vote on named executive officer compensation for 2025 is on the agenda.
Board recommends approval of the executive compensation package.
Latest events from Baxter International
- Shareholders will vote on key governance, compensation, and board structure changes, all recommended for approval.BAX
Proxy filing23 Mar 2026 - Proxy seeks approval for Board refreshment, pay practices, auditor, and sustainability focus.BAX
Proxy Filing13 Mar 2026 - Oil price exposure halved, new operating model boosts efficiency, and margin recovery expected.BAX
Barclays 28th Annual Global Healthcare Conference11 Mar 2026 - Stable fundamentals, prudent 2026 outlook, and focus on innovation and deleveraging.BAX
Citi’s 2026 Unplugged MedTech and Life Sciences Access Day26 Feb 2026 - Q4 sales up 8%, but adjusted EPS down 24%; 2026 outlook flat to slightly improving.BAX
Q4 202516 Feb 2026 - Q2 sales and adjusted EPS beat guidance; net loss from goodwill impairment; guidance raised.BAX
Q2 20242 Feb 2026 - Separation of the kidney business and operational focus set the stage for growth and margin expansion.BAX
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - Portfolio transformation and innovation drive growth, with new launches and pricing gains ahead.BAX
Jefferies Global Healthcare Conference1 Feb 2026 - Vantive sale accelerates deleveraging; post-separation growth driven by innovation and margin gains.BAX
2024 Wells Fargo Healthcare Conference22 Jan 2026